Iloprost Zentiva

Iloprost, the active ingredient in Iloprost Zentiva, is a prostacyclin analog presented as a solution for injection for intravenous use. It treats pulmonary arterial hypertension in adult patients. GNH USA supplies Iloprost Zentiva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost is a prostacyclin analog used in the management of pulmonary arterial hypertension, a disease characterized by elevated pulmonary vascular resistance. Pulmonary arterial hypertension: improves exercise tolerance and delays clinical worsening. Chronic thromboembolic pulmonary hypertension: reduces pulmonary artery pressure and enhances functional class.

Common Side Effects: - Headache: mild to moderate pain often occurring during infusion. - Flushing: warmth and redness of the skin. - Nausea: occasional upset stomach. - Jaw pain: discomfort during chewing. - Hypotension: transient drop in blood pressure. - Infusion site pain: irritation at the injection site.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in the lungs. - Severe hypotension: marked blood‑pressure fall requiring intervention. - Bleeding: increased risk due to platelet inhibition. - Arrhythmia: irregular heart rhythm. - Thrombocytopenia: low platelet count. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, consider the following precautions. - Monitor blood pressure: check regularly for hypotension. - Assess bleeding risk: avoid concurrent anticoagulants when possible. - Evaluate renal function: adjust use if impairment is present. - Avoid use in recent myocardial infarction: increased ischemic risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost may interact with several drug classes. Major Interactions (Avoid): - Concomitant potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other prostacyclin analogs: additive vasodilatory effect. Moderate Interactions (Monitor Closely): - Phosphodiesterase inhibitors: may enhance vasodilation. - CYP450 substrates: monitor despite limited metabolism. - Beta‑blockers: may mask tachycardia response.